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AIMS
Spironolactone is widely used to treat heart failure, hypertension and liver disease with increased usage in recent years.
Spironolactone has endocrine effects that could inﬂuence cancer risks and historical reports suggest possible links with increased
risk of certain types of cancer. The aim of this study was to assess the effect of spironolactone exposure on cancer incidence.
METHODS
A pharmacoepidemiological propensity score-matched cohort study was performed to assess the effect of spironolactone
exposure on cancer incidence. Cox proportional hazards models were used to analyse time to ﬁrst diagnosis of each prespeciﬁed
cancer and hazard ratios for spironolactone exposure are presented. The setting for the study was UK primary care using the
Clinical Practice Research Datalink. The participants were 74 272 patients exposed to spironolactone between 1986 and 2013,
matched 1:2 with unexposed controls. The prespeciﬁed primary outcomes were the ﬁrst incidence of ovarian, endometrial,
pancreatic, colorectal, prostate, renal cell, pharyngeal and thyroid cancers, and myelomonoblastic/-cytic leukaemias. Secondary
outcomes were the remaining 27 types of cancer.
RESULTS
There was no evidence of an increased risk of any cancer associated with spironolactone use. Spironolactone use was associated
with a signiﬁcantly lower risk of prostate cancer (hazard ratio 0.69; 95% conﬁdence interval 0.60–0.80, P < 0.001).
CONCLUSIONS
In this study, spironolactone use was associated with a lower incidence of prostate cancer, the most common cancer in men in the
UK. The possible mechanisms and clinical implications merit further investigation.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• The use of spironolactone has increased in recent years particularly for the treatment of hypertension and heart failure.
• Spironolactone has hormonal effects that could potentially inﬂuence the incidence of certain types of cancer.
• Historical reports have associated spironolactone use with increased risk of certain cancers.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any me-
dium, provided the original work is properly cited, the use is non-commercial and no modiﬁcations or adaptations are made.
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WHAT THIS STUDY ADDS
• Spironolactone exposure was not associated with an increased incidence of cancers.
• Our study suggests that spironolactone use may be associated with a lower incidence of prostate cancer (the most
common cancer in men).
• Further studies are needed to investigate the mechanisms involved and clinical implications of these ﬁndings.
Introduction
Spironolactone is an aldosterone antagonist commonly
used to treat liver disease and heart failure. Its use in heart
failure and hypertension has increased greatly in recent
years [1, 2]. Although spironolactone has a licence from
the Medicines and Healthcare Products Regulatory Agency
for other indications, spironolactone is not currently ap-
proved for the indication of hypertension in the UK. This
approval was withdrawn in 1988 after animal studies sug-
gested an increase in myelomonocytic leukaemia with po-
tassium canrenoate, a similar compound that, like
spironolactone, is metabolised to canrenone. The British
National Formulary entry for spironolactone carries the
caution, ‘potential metabolic products carcinogenic in ro-
dents’ [3]. The 2012 International Agency for Research on
Cancer monograph for spironolactone summarises the data
on possible associations of spironolactone with different
cancers and concludes that ‘there is inadequate evidence in
humans for the carcinogenicity of spironolactone’ while
‘there is limited evidence in experimental animals for the car-
cinogenicity of spironolactone’. Overall, it concludes that
‘spironolactone is not classifiable as to its carcinogenicity to
humans (Group 3)’ [4].
The metabolism of spironolactone is complicated and not
well understood [5]. In addition to inhibiting the mineralo-
corticoid receptor, spironolactone, either directly or via its
active metabolites, also has antiandrogenic and progesto-
genic actions. Therefore, it is plausible that it might increase
the risk of hormonally dependent cancers including breast,
ovarian, endometrial, pancreatic and colorectal cancers.
Spironolactone could potentially either increase or decrease
the risk of prostate cancer due to a complex combination of
antagonist and partial agonist effects on androgen receptors,
possible 5α-reductase inhibition effects and effects on testos-
terone metabolism [6, 7].
Previous studies have suggested possible associations of
spironolactone use with certain cancers in humans includ-
ing pharyngeal [8], thyroid [9] and renal cancers [10–14].
However, these have involved very small numbers of cases,
or have been confounded due to difﬁculty in separating
spironolactone use from the effects of other drugs or
hypertension on renal cancer. There have also been reports
of possible associations with breast cancer in some studies
[15–21] but in a large cohort study, we found no association
with breast cancer [22]. This was conﬁrmed in another re-
cent study that investigated the relationship between
spironolactone use and risk of breast and gynaecological
cancers [23]. Spironolactone, ﬁrst marketed in 1953 [24],
is now extensively used. It is therefore important to clarify
any association with cancers of all types.
Methods
Primary and secondary objectives
The primary objective was to test the hypothesis that
spironolactone exposure inﬂuences the development of nine
prespeciﬁed cancers, either because of biologically plausible
mechanisms or because previous observational or animal
studies had suggested an association (Table 1). The secondary
objective was to screen 27 other types of cancer for an effect
of spironolactone exposure.
Study design
The study used a cohort design in the UK Clinical Practice
Research Datalink (CPRD) database to compare the incidence
of cancers in patients exposed and unexposed to
spironolactone.
Study population
The study population consisted of patients who were regis-
tered with a general practitioner in the CPRD between 1986
and February 2013. CPRD (formerly known as the General
Practice Research Database) [25] is a longitudinal primary
care database containing details of patients’ demographics,
medical diagnoses, referrals to consultants and hospitals,
and primary care prescriptions from a representative sample
of primary care practices in the UK covering about 7% of
the UK population. Hospital Episode Statistics (HES) data
are available for a subset of CPRD practices (57%), allowing
linkage with hospital discharge diagnostic data [26].
Ethical approval
The study protocol was reviewed and approved by the
Independent Scientiﬁc Advisory Committee of the CPRD.
Follow-up period
Enrolment started when ‘up-to-standard’ data were available
for a practice, or when a patient registered after this date.
The ‘up-to-standard’ date is deﬁned as the date from which
the practice data met various quality control criteria set by
CPRD. This ensured that we only used data that were consid-
ered to be ‘up-to-standard’ as deﬁned by CPRD. The last
follow-up date was deﬁned as the practice’s last data collec-
tion date, or the patient’s transfer out date from the practice
(includes transfer out due to death) if earlier. In sensitivity
analyses we also used a patient’s last contact date (last visit
to practice, proving that the patient was still contributing to
that practice’s data) as their last follow-up date.
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Study subjects
Spironolactone cohort. We identiﬁed patients who received at
least two prescriptions for spironolactone during the study
period. These patients formed the spironolactone exposed
cohort. We deﬁned an index date for each patient as the
date of the second prescription for spironolactone. The ﬁrst
prescription date was not used to avoid introducing
immortal time bias. If a patient’s index date was at least 1
year after their enrolment date, we classiﬁed them as an
incident user. Others were classiﬁed as prevalent users.
The exposure of each patient was characterised by mean
dose and the proportion of days for which drug was
prescribed between ﬁrst and last exposure. Mean dose was cal-
culated as the weighted mean of the prescribed doses, taking
account of the days of supply provided by each prescription.
The ﬁrst 180 days following the estimated last exposure date
was classiﬁed as exposed follow-up in the statistical models
to allow for a lag time in the diagnosis of new cases (Figure 1).
Comparator cohorts. We constructed a comparator cohort by
matching patients on a propensity score, namely the
probability of exposure to spironolactone estimated from a
logistic regression model. The predictors in this model were
age, calendar year of entry to study, use of combined oral
contraceptive pills or hormone replacement therapy,
smoking status, alcohol intake, body mass index (BMI),
family history of cancer, use of drugs that may be protective
against cancer (aspirin, metformin, digoxin and angiotensin-
converting-enzyme inhibitors) and history of hypertension,
heart failure, liver disease or diabetes mellitus. The
Townsend score for socioeconomic status was available in
57% of practices and was included in the estimation of
propensity scores in practices that provided it. If a patient’s
tobacco consumption, alcohol intake or body mass index
was not recorded we classiﬁed it as such to ensure that
patients with missing information were equally represented
in the exposed and control cohorts.
Figure 1
Classiﬁcation of follow-up time in exposed patients. Summary of classiﬁcation of follow-up time in the spironolactone exposed patients
Table 1
Prespeciﬁed primary outcomes
Prespeciﬁed primary outcomesa Reasons for prespecifying as primary outcomes
Ovarian cancer
Endometrial cancer
Pancreatic cancer
Colorectal cancer
A higher incidence might be expected on the basis of
biologically plausible hormonal effects of spironolactone.
Prostate cancer A higher or lower incidence might be expected on the
basis of biologically plausible hormonal effects of spironolactone.
Renal cell cancer
Pharyngeal cancer
Thyroid cancer
Myelomonoblastic/myelomonocytic leukaemia
A higher incidence might be expected on the basis of
previously reported associations in other observational or animal studies.
aFirst incidence during the follow-up period of each type of cancer
Spironolactone and risk of incident cancers
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Time-dependent covariates (age, history of exposure and
history of disease) were evaluated on each patient’s index
date, and in order to do this for potential control patients
we assigned index dates randomly by incidence density
sampling from the distribution of dates in the exposed
cohort. Patients were excluded if they had a history of any
cancer or ascites on their index date.
For each exposed patient, two control patients were se-
lected at random from the same practice, matched on deciles
of the propensity score and sex (to ensure that the cohorts
were well matched in the analyses of sex-speciﬁc cancers).
Study outcomes
Outcomes were deﬁned as the ﬁrst incidence of cancer during
the follow-up period, classiﬁed as one of 36 types (see online
Appendix for code lists). We speciﬁed nine of these as pri-
mary outcomes in advance: ovarian, endometrial, pancreatic
and colorectal cancers (a higher incidence may be expected
on the basis of biologically plausible hormonal effects of
spironolactone); prostate cancer (biologically plausible hor-
monal effects may lead to either a higher or lower incidence);
renal cell cancer, pharyngeal cancer, thyroid cancer and
myelomonoblastic/myelomonocytic leukaemia (previously
reported associations in other observational or animal studies
suggest a higher incidence). Breast cancer was not speciﬁed as
a primary outcome in this study because we had previously
completed a detailed study in CPRD that showed no associa-
tion between spironolactone use and breast cancer incidence
in women aged over 55 years [22].
Myelomonoblastic/-cytic leukaemia was treated as a
primary outcome despite occurring in only 440 patients in
the database, 12% below the arbitrary threshold of 500 spec-
iﬁed in the protocol for re-designating it as a secondary
outcome.
The remaining 27 types of cancer were regarded as sec-
ondary outcomes. Detailed information on cancer staging
was not available in CPRD.
Statistical analysis
The time from index date to ﬁrst diagnosis of each cancer was
analysed using a proportional hazards model. Calendar year
and age were treated as time dependent variables. For the ex-
posed cohort, we also included a time dependent ﬂag variable
indicating discontinuation of spironolactone for >180 days.
All other covariates were evaluated on the index date.
Hazard ratios were estimated for the exposed and
discontinued periods in the spironolactone cohort relative
to the control cohort, with exposed time in incident and
prevalent users classiﬁed separately in sensitivity analyses.
All the covariates used to estimate the propensity scores were
also used in these models. Z-scores (the estimated hazard
ratios divided by their standard errors) were calculated for
all 36 types of cancer. Under the null hypothesis that the
incidence of all cancers is unaffected by exposure to
spironolactone, these scores would have a standard normal
distribution. A Q-Q plot was produced to compare quantiles
of the observed distribution with those expected under the
null hypothesis.
Confounding by indication may be severe in the analysis
of liver cancer because spironolactone is indicated for some
its symptoms, but at a higher dose than is generally pre-
scribed for heart failure. Therefore, for liver cancer only, pa-
tients who were prescribed >50 mg/day of spironolactone,
and their control patients, were excluded from the analyses.
Sensitivity and subgroup analyses. We examined the
sensitivity of our results for the primary outcomes to the
deﬁnition of the follow-up period, and to the inclusion of
HES data. In the primary analyses patients were followed-up
until their practice’s last data collection date, unless they
transferred out of the practice or died at an earlier date. In
one set of sensitivity analyses, follow-up was censored at the
date of last contact with each patient (excluding
administrative records). In another, we included outcomes
identiﬁed from HES as well as the CPRD, but restricted the
analyses to the 273 practices with linked HES data (available
for April 1997 to March 2012).
Results
We found 74 883 patients with at least two prescriptions for
spironolactone and no prior diagnosis of cancer or ascites
recorded in the CPRD. The exposed cohort in this study
consisted of the 74 272 (99%) of these patients for whom
we found at least one matched control. Spironolactone
exposure is summarised in Table 2. We classiﬁed 52 671
patients (71%) as incident users. Their median follow-up time
was 11.3 years (9.6 years exposed and 1.0 years after
discontinuation). The median follow-up time was 3.1 years
for prevalent users. The mean dose was higher in prevalent
users (47 mg vs. 25 mg), and the proportion of days for which
drug was prescribed between ﬁrst and last exposure was high
in both groups.
The median follow-up time in the control cohort was
11.5 years (interquartile range 6.9–15.5). Baseline characteris-
tics of the control and exposed cohorts are summarised in
Table 3. There was a good balance at baseline for most
potential risk factors. There was an imbalance in the
prevalence of heart failure and liver disease, for which
spironolactone may be indicated, and the use of digoxin
and angiotensin-converting-enzyme inhibitors, also used to
treat heart failure, despite matching on a propensity score
that included them. Events per 100 000 patient years for the
36 types of cancer deﬁned in this study are given in Table 4.
Liver cancer events were higher in the exposed than control
cohorts as might be expected due to confounding by indica-
tion, but the bias was reduced when we excluded patients
on >50 mg/day spironolactone.
Z-scores for the hazard ratios for each type of cancer in
three sets of sensitivity analyses are shown in Figure 2. In
all three analyses, the z-score for prostate cancer was nega-
tive and highly signiﬁcant. In the primary analysis, which
followed patients to their practice’s last data collection date,
spironolactone use was associated with a signiﬁcantly lower
risk of prostate cancer (hazard ratio 0.69; 95% conﬁdence
interval 0.60–0.80, P < 0.001). In the primary analysis, the
hazard ratio for lung cancer was also nominally signiﬁcant,
and in the sensitivity analysis that censored patients at last
contact, the hazard ratio for pancreatic cancer was
I. S. Mackenzie et al.
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Table 2
Follow-up time and characteristics of spironolactone exposure
Median (interquartile range)
Overall Incident users Prevalent users
Subjects n = 74 272 n = 52 671 n = 21 601
Total follow-up time (years) 9.2 (4.2,13.8) 11.3 (7.1,15.3) 3.1 (1.1,7.2)
Exposed follow-up time (years) 6.9 (2.4,12.2) 9.6 (5.5,13.7) 1.0 (0.2,3.0)
Time after discontinuation (years) 1.3 (0.2,4.2) 1.0 (0.2,3.4) 2.2 (0.3,6.8)
Mean daily dose (mg) 25 (25,50) 25 (25,50) 47 (25,75)
Coverage (%) 98 (79,100) 99 (81,100) 96 (74,100)
Table 3
Distribution of covariates in the control and exposed cohorts
Control cohort Exposed cohort
n % n %
Total 147 953 100.0 74 272 100.0
Sex
Male 67 441 45.6 33 865 45.6
Female 80 512 54.4 40 407 54.4
Age group
Under 40 years 9796 6.6 4635 6.2
40–49 years 8994 6.1 4602 6.2
50–59 years 16 574 11.2 8065 10.9
60–69 years 28 142 19.0 13 887 18.7
70–79 years 39 622 26.8 20 219 27.2
80–89 years 36 087 24.4 18 403 24.8
≥90 years 8738 5.9 4461 6.0
Year of index date
1987–1995 13 760 9.3 6917 9.3
1996–2000 19 999 13.5 10 037 13.5
2001–2005 50 809 34.3 25 508 34.3
2006–2010 46 108 31.2 23 143 31.2
2011–2013 17 277 11.7 8667 11.7
History of drug use
Oral contraceptivesa 4692 3.2 2368 3.2
Hormone replacement therapya 12 942 8.7 6332 8.5
Metformin 15 068 10.2 8932 12.0
Aspirin 65 507 44.3 36 310 48.9
Digoxin 14 381 9.7 16 781 22.6
ACE inhibitors 69 678 47.1 41 083 55.3
Family history of cancer 2629 1.8 1269 1.7
(continues)
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Table 3
(Continued)
Control cohort Exposed cohort
n % n %
Medical history
Hypertension 75 674 51.1 36 634 49.3
Heart failure 15 546 10.5 25 552 34.4
Liver disease 3412 2.3 4773 6.4
Diabetes mellitus 24 957 16.9 14 457 19.5
Abdominal pain 26 881 18.2 14 233 19.2
BMI 25–30 kg m2 82 386 55.7 42 121 56.7
BMI > 30 kg m2 44 071 29.8 23 452 31.6
> 21 units alcohol/week 12 086 8.2 6323 8.5
Never smoked 61 781 41.8 31 012 41.8
> 20 cigarettes/day 7357 5.0 3798 5.1
1 16 685 11.3 7998 10.8
2 18 496 12.5 9199 12.4
3 18 565 12.5 9342 12.6
4 17 705 12.0 8909 12.0
5 11 835 8.0 6119 8.2
Not available 64 667 43.7 32 705 44.0
aNumber and percentage of women
ACE = angiotensin-converting enzyme; BMI = body mass index
Table 4
Cases and incidence (events per 100 000 patient–years) for 36 cancer types in the exposed and control cohorts
Male Female
Exposed Control Exposed Control
Patient–years follow-up (105) 3.005 5.444 3.510 6.324
n phtpy n phtpy n phtpy n phtpy
Primary outcomes
Prostate 450 138 1424 179 N/A
Colorectal 264 81 647 81 242 63 587 64
Endometrial N/A 69 18 157 17
Ovarian N/A 64 17 145 16
Pancreatic 42 13 115 14 68 18 136 15
Renal 26 8 56 7 25 6 29 3
MML 14 4 35 4 13 3 22 2
Pharyngeal 8 2 21 3 5 1 9 1
Thyroid 4 1 5 1 6 2 21 2
Secondary outcomes
Minor skin cancers 655 201 1635 205 629 163 1512 166
(continues)
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nominally signiﬁcant. There is a 30% chance of at least one
of the remaining 35 tests being signiﬁcant at P < 0.01 under
the null hypothesis that spironolactone has no effect. The
hazard ratios relative to controls for each primary outcome
during periods of exposure to spironolactone are given in
Table 5.
In the primary analysis for prostate cancer the hazard
ratio associated with spironolactone exposure was 0.73
(0.63–0.85) in incident users and 0.58 (0.43–0.78) in
prevalent users (Table 6). The hazard ratio for high dose vs.
low dose was 0.74 (0.51–1.06), and prevalent users in this
study received higher doses of spironolactone than incident
users. In patients who discontinued spironolactone, the
hazard ratio for prostate cancer was 2.08 (1.48–2.92) relative
to their exposed period.
Prostate speciﬁc antigen (PSA) levels in exposed and
control patients in 6months periods for 2 years before and af-
ter their index dates are shown in Figure 3A. Levels were sim-
ilar in the two cohorts before the index date, but lower in the
spironolactone cohort after the index date. PSA levels con-
verged again within 6 months of discontinuation of
spironolactone (Figure 3B).
Table 4
(Continued)
n phtpy n phtpy n phtpy n phtpy
Breast N/A 504 131 1103 121
Lung 314 96 701 88 231 60 485 53
Bladder 132 40 385 48 43 11 137 15
Carcinoma in situ 130 40 297 37 305 79 627 69
Oesophagus 89 27 185 23 42 11 117 13
Squamous cell carcinoma of skin 66 20 144 18 42 11 105 12
Stomach 62 19 141 18 38 10 99 11
Leukemia 37 11 114 14 28 7 62 7
Melanoma of skin 43 13 103 13 44 11 113 12
Non Hodgkin lymphoma 50 15 99 12 58 15 102 11
Other malignant neoplasm of skin 44 13 84 11 44 11 85 9
Myeloma 32 10 68 9 25 6 55 6
Mesothelioma 17 5 66 8 4 1 8 1
Other lymphatic and haemopoietic 28 9 62 8 32 8 71 8
Lip and oral cavity 29 9 61 8 18 5 41 5
Other respiratory organs 19 6 61 8 13 3 18 2
Other genitourinary organs 15 5 58 7 38 10 76 8
Other cancers 31 9 58 7 24 6 59 6
Liver 99 30 54 7 38 10 21 2
Livera 35 14 41 7 8 3 15 3
Kidney 30 9 54 7 18 5 32 4
Other digestive organs 22 7 48 6 28 7 63 7
Nervous system 13 4 39 5 8 2 31 3
Other bone and connective tissue 11 3 17 2 13 3 27 3
Anus 5 2 8 1 3 1 15 2
Hodgkins lymphoma 5 2 7 1 3 1 11 1
Melanoma in situ 4 1 4 1 4 1 3 0
N/A Not applicable; MML, myelomonoblastic/myelomonocytic leukaemia’ phtpy, per 100 000 patient–years. We did not analyse a very small
number of breast cancer cases in men.
aExcluding patients exposed to >50 mg/day spironolactone and their controls. Events per 100 000 patient–years are rounded to nearest whole
number
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Figure 2
Q-Q plots for hazard ratios associated with exposure to spironolactone. Three sensitivity analyses are shown: (A) Follow-up to last data collection;
(B) Follow-up to last contact with patient recorded in the Clinical Practice Research Datalink; (C) Primary outcomes in practices with Hospital
Episode Statistics data available. Cancers with hazard ratios that are signiﬁcant at P < 0.01 are labelled. Prostate cancer is highly signiﬁcant in
all three sensitivity analyses, which use different randomly selected control cohorts. Under the null hypothesis of no effect of exposure to
spironolactone, hazard ratios divided by their standard deviations (z scores) would have a standard normal distribution and quantiles of the
observed distribution would be close to the theoretical quantiles of the standard normal distribution
Table 5
Hazard ratios (95% conﬁdence intervals) for primary outcomes
Follow-up to last data
collection date Follow-up to last contact
Subgroup with HES,last
data collection date
Prostate 0.69 (0.60,0.80), P < 0.001 0.72 (0.63,0.82), P < 0.001 0.82 (0.71,0.94), P = 0.006
Colorectal 0.91 (0.80,1.04), P = 0.155 0.90 (0.79,1.02), P = 0.111 1.01 (0.88,1.15), P = 0.901
Endometrial 0.90 (0.63,1.30), P = 0.579 1.01 (0.71,1.44), P = 0.942 1.24 (0.89,1.73), P = 0.201
Ovarian 1.28 (0.90,1.81), P = 0.168 1.14 (0.81,1.60), P = 0.444 1.30 (0.94,1.80), P = 0.118
Pancreatic 1.22 (0.93,1.60), P = 0.150 1.48 (1.13,1.94), P = 0.005 1.19 (0.91,1.56), P = 0.206
MML 1.44 (0.84,2.47), P = 0.182 1.08 (0.64,1.82), P = 0.765 1.90 (1.16,3.11), P = 0.011
Renal 1.46 (0.95,2.24), P = 0.085 1.28 (0.85,1.92), P = 0.236 0.94 (0.69,1.27), P = 0.669
Pharyngeal 0.76 (0.32,1.82), P = 0.540 1.07 (0.44,2.63), P = 0.880 1.01 (0.47,2.19), P = 0.971
Thyroid 0.67 (0.23,2.00), P = 0.478 0.53 (0.20,1.39), P = 0.196 0.70 (0.23,2.11), P = 0.522
Hospital Episode Statistics (HES) data are available for a subset of Clinical Practice Research Datalink practices (57 %), allowing linkage with hospital
discharge diagnostic data
I. S. Mackenzie et al.
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Discussion
Principal findings
This study provided no support for the hypothesis that
spironolactone exposure increases the riskofnineprespeciﬁed
cancers, or 27 other cancers. Two different cancers had nomi-
nally signiﬁcant hazard ratios >1 in separate sensitivity
analyses, but this was not an unlikely outcome when 35
cancers (i.e. excluding prostate) were screened. However, for
uncommoncancers, the conﬁdence limits of ourﬁndingswere
broad.
The study also found a reduced risk of prostate cancer in a
large cohort of patients exposed to spironolactone in three
sensitivity analyses using different control cohorts. This is
consistent with our a priori hypothesis that spironolactone
exposure might either increase or reduce the incidence of
prostate cancer, based on its known hormonal effects and
the likely partially hormonal basis of this cancer. We found
a statistically signiﬁcant 31% reduction in the incidence of
prostate cancer with spironolactone exposure. Prostate
cancer is the most common cancer in men (nearly 50 000
new cases per year in the UK) [27] and its treatment causes
much morbidity; our ﬁnding that the incidence of prostate
cancer was reduced in men taking spironolactone suggests
that it may have a role in primary prevention of prostate
cancer. There was some evidence that the incidence of pros-
tate cancer increased after discontinuation of spironolactone,
but a further study matching patients at the time of discon-
tinuation would be required to conﬁrm this.
Strengths and weaknesses of the study
This study was carried out in CPRD, a UK primary care
database that is representative of the general UK population.
However, because the study was observational, all potentially
confounding factors may not have been fully controlled for,
despite matching on propensity score and adjusting for
covariates. Other limitations include the accuracy of coding
for the exposure (for example, spironolactone prescribing
from secondary care would not have been detected),
outcomes and covariates, missing data, and unrecorded
confounding factors. Random errors arising from database
coding errors were likely to affect exposed and nonexposed
cohorts similarly and would bias the results towards the null.
The codes used in the study were cross-checked by a cancer
specialist and two clinical pharmacologists. Some risk factors
for cancer such as family history, genetic abnormalities and
ethnicity are poorly recorded in CPRD or could not be fully
assessed, but we included all relevant covariates for which
data were available. We conducted one set of sensitivity
analyses that included HES, to assess the effect of missing
outcome events in CPRD, and another that censored follow-
up time at last contact instead of last data collection date, to
assess the effect of assuming that patients were present until
the later date.
There were too few cases of acute myelomonocytic/
myelomonoblastic leukaemia to draw ﬁrm conclusions on
whether there was any association with spironolactone
exposure. However, we found no clear evidence of increased
risk.
Table 6
Hazard ratios (95% conﬁdence intervals) for prostate cancer by
prevalent or incident use of spironolactone and dose
Hazard ratio (95% CIs)
Incident users vs. controls 0.73 (0.63,0.85), P < 0.001
Prevalent users vs. controls 0.58 (0.43,0.78), P < 0.001
Medium vs. low dose 0.99 (0.78,1.26), P = 0.957
High vs. low dose 0.74 (0.51,1.06), P = 0.100
Discontinued vs. low dose 2.08 (1.48,2.92), P < 0.001
Low dose <37.5 mg/day, Medium dose 37.5–74.9 mg/day, High
dose ≥75 mg/day
Figure 3
Mean prostate speciﬁc antigen (PSA) in exposed and control patients
(A) for 2 years before and after their index dates and (B) for 2 years
before and after discontinuation of spironolactone. PSA levels were
similar in the exposed and control cohorts before the index date,
but lower in the spironolactone cohort after the index date
suggesting that spironolactone exposure is associated with lower
PSA levels. Within 2 months of spironolactone discontinuation, PSA
levels in the exposed cohort returned to levels not signiﬁcantly
different to those in control patients
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Comparison with other studies
There have been no other recent studies investigating the
relationship between spironolactone exposure and prostate can-
cer incidence. The Prostate Cancer Prevention Trial reported
that ﬁnasteride, a 5-α reductase inhibitor, signiﬁcantly reduced
the relative risk of prostate cancer in the general population by
24.8% [28]. However, there wasmore high-grade prostate cancer
in theﬁnasteride group than the placebo group. After 18 years of
follow-up, there was no signiﬁcant difference in survival rates
between the two groups.
A recent high-throughput chemical screen suggested a
potential mechanism by which spironolactone impairs
cancer cell survival by inhibiting homology directed repair
and suggested that spironolactone might be a new candidate
for chemotherapy [29]. In addition, recent work has
suggested that spironolactone may enhance tumour cell
elimination by natural killer cells in multiple colon cancer
cell lines by activating the ATM-Chk2-mediated checkpoint
pathway via actions on the retinoid X receptor γ (RXRγ)
[30]. However, in the current study, we only found a signiﬁ-
cant association of spironolactone use with reduced inci-
dence of prostate cancer.
Meaning of the study
The results of this study allay concerns that spironolactone
exposure is associated with an increased risk of cancers. In
fact, our ﬁndings suggest that it is associated with reduced
incidence of prostate cancer. Because spironolactone is
generally well tolerated and is useful in the treatment of other
conditions (hypertension and heart failure) commonly
affecting older men at risk of prostate cancer, it may have
potential in the primary prevention of prostate cancer, partic-
ularly in high-risk patients with other potential indications
for spironolactone therapy. At present, patients considered
to be at high risk of prostate cancer include older men, men
of African descent and men with a positive family history of
prostate cancer in a ﬁrst-degree relative.
Future research
Firstly, our ﬁndings need to be conﬁrmed independently in
observational studies in different populations. If conﬁrmed,
further exploration of the possible effects of spironolactone
in the primary prevention of prostate cancer and its place, if
any, in the treatment of early stage prostate cancer (currently
often managed by active surveillance) [31] and effects on
overall mortality in prostate cancer in randomised controlled
clinical trials would then be needed before its use could be
recommended. Investigation of whether it might accelerate
the progression of advanced prostate cancer, as reported in a
case study in a single patient [32], would also be required. In
summary, this study identiﬁed no increased risk of cancers
in people exposed to spironolactone. Further work is required
to establish whether spironolactone has a role in the preven-
tion of prostate cancer.
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